GlassScriptPhysician profile
Sharon A Johnson
NPI 1497087894
$16,193.97
in general payments reported to CMS, 2019-2025
52 companies · $3,839 in 2025
The $3,839 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,465 · 2022: $2,904 · 2023: $3,540 · 2024: $2,446 · 2025: $3,839.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,825.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,825.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,070.55 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $1,421.65 | 2021-2025 | Ingrezza, Ongentys |
| Ucb, INC. | $1,278.89 | 2021-2025 | Briviact, Rystiggo, Fintepla |
| Teva Pharmaceuticals USA, INC. | $870.60 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Eisai INC. | $758.71 | 2023-2025 | |
| Jazz Pharmaceuticals INC. | $555.00 | 2022-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $539.44 | 2022 | |
| Lilly USA, LLC | $497.62 | 2021-2025 | Reyvow, Emgality, Kisunla |
| Amgen INC. | $493.27 | 2021-2025 | Uplizna |
| Acadia Pharmaceuticals INC | $467.80 | 2021-2025 | Nuplazid |
| Argenx US, INC. | $407.62 | 2023-2025 | Vyvgart, Vyvgart Hytrulo |
| Novartis Pharmaceuticals Corporation | $402.56 | 2021-2025 | |
| Supernus Pharmaceuticals, INC. | $378.50 | 2021-2025 | Qelbree |
| Biohaven Pharmaceuticals, INC. | $336.14 | 2021 | |
| Kyowa Kirin, INC. | $329.62 | 2021-2024 | Nourianz |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $326.99 | 2021-2025 | |
| Acorda Therapeutics, INC | $314.57 | 2021-2024 | Inbrija |
| Amneal Pharmaceuticals LLC | $292.22 | 2021-2025 | Rytary, Crexont, Ongentys 50mg Capsules 30 |
| Pfizer INC. | $289.07 | 2023-2025 | |
| Abbott Laboratories | $278.34 | 2023 | Infinity |
| Merz Pharmaceuticals, LLC | $239.13 | 2021-2025 | Xeomin, Inbrija |
| Horizon Therapeutics Plc | $225.10 | 2021-2023 | Uplizna |
| Biogen, INC. | $208.57 | 2021-2025 | Vumerity, Spinraza |
| Ipsen Biopharmaceuticals, INC | $187.37 | 2022-2024 | Dysport |
| Lundbeck LLC | $182.89 | 2021-2025 | Vyepti |
| Neurelis, INC. | $178.76 | 2021-2025 | Valtoco |
| Tg Therapeutics, INC. | $158.08 | 2025 | |
| Harmony Biosciences LLC | $141.74 | 2022-2023 | Wakix |
| Emd Serono, INC. | $132.49 | 2021-2022 | |
| Mdd US Operations, LLC | $131.17 | 2024-2025 | Gocovri |
| Takeda Pharmaceuticals U.S.A., INC. | $118.95 | 2022-2025 | Gammagard, Hyqvia |
| Otsuka America Pharmaceutical, INC. | $113.16 | 2023-2025 | Rexulti, Nuedexta |
| Alexion Pharmaceuticals, INC. | $93.36 | 2023 | Ultomiris |
| Genzyme Corporation | $92.05 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $82.16 | 2021 | |
| Genentech USA, INC. | $77.89 | 2024-2025 | Ocrevus Zunovo |
| Amylyx Pharmaceuticals, INC. | $62.33 | 2023 | Relyvrio |
| Vanda Pharmaceuticals INC. | $61.02 | 2025 | Ponvory |
| Adamas Pharmaceuticals, INC. | $57.44 | 2021 | |
| Ani Pharmaceuticals, INC. | $52.27 | 2025 | Purified Cortrophin Gel |
| Allergan, INC. | $51.51 | 2022 | |
| Grifols USA, LLC | $33.13 | 2021 | |
| Springworks Therapeutics, INC. | $27.99 | 2025 | Gomekli |
| Upsher-Smith Laboratories LLC | $25.60 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $24.85 | 2025 | Wainua |
| Tanabe Pharma America, INC. | $24.45 | 2021-2022 | |
| Csl Behring | $24.39 | 2021 | |
| Ge Healthcare | $20.98 | 2022 | |
| Medtronic, INC. | $16.31 | 2021 | |
| Janssen Biotech, INC. | $15.30 | 2025 | |
| Avanir Pharmaceuticals, INC. | $12.71 | 2022 | |
| Catalyst Pharmaceuticals, INC. | $11.66 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.